| Name | Title | Contact Details |
|---|
OXiGENE is a biopharmaceutical company developing new and improved therapeutics that have the potential to deliver significant medical benefits to patients with cancer and serious medical conditions. Our primary focus is developing first-in-class anti-vascular drugs referred to as vascular disrupting agents (VDAs). Our lead compound in clinical development is fosbretabulin. VDAs are a new and highly differentiated class of anti-vascular drug that target existing tumor vasculature, leading to extensive tumor cell death. VDAs target the tumor vasculature rather than the tumor cells and therefore have broad potential therapeutic utility in cancer. Because VDAs act differently than anti-angiogenic drugs or cytotoxic chemotherapy drugs, VDAs are potentially complementary with anti-angiogenic drugs and chemotherapeutic agents. OXiGENE has ongoing VDA drug development programs and is committed to advancing the science of VDAs and their potential as innovative therapies to address unmet medical needs.
Htv Systems Ltd is a Mississauga, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Abilities Foundation of Nova Scotia is a Halifax, NS-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
We are a startup up medical device company whose sole focus and mission are to transform patient care through innovative Med-tech solutions. Our initial product is a minimally invasive Prostate Volume Measurement Device to help doctors evaluate a patient`s prostate health. Our solution includes a controller that receives measurement data from an encoder device. The encoder a disposable, single-use component made with an injection molding process. We are in the proof of concept phase and want to move to test marketing trials and production by end of 2020.
Desert AIDS Project is a Palm Springs, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.